Clinical trials
Metastatic Pancreatic Adenocarcinoma clinical trials
Below are recruiting metastatic pancreatic adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 248 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07627191RecruitingEarly Phase 1
GLP-1 drug plus standard chemo for first-line advanced cancers
This trial tests whether adding a GLP-1 receptor agonist (a drug used for diabetes and weight loss) to standard chemotherapy can help people with advanced pancreatic, colorectal, or liver cancer. It is for people who have not yet started treatment for their metastatic disease and have a BMI of 25 or higher.
Tucson, ArizonaAges 18–99 - NCT07478523RecruitingPhase 2
FAPI-PET scan for initial screening of pancreatic and bile duct cancers
This trial tests a new imaging method called FAPI-PET to see if it can better detect pancreatic and bile duct cancers at an early stage. It may help doctors decide on the best treatment plan for you.
PessacAges 18 years+ - NCT07784374RecruitingPhase 2
Study of new targeted therapies for advanced pancreatic cancer
This trial tests three new targeted drug combinations for pancreatic cancer that has a specific genetic change (KRAS G12D). They are comparing the study drug alone versus combining it with other investigational drugs to see which works better.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07705919RecruitingPhase 1/Phase 2
MRI scans to monitor borderline resectable pancreatic cancer treatment
This study uses MRI scans to see how well chemotherapy and radiation work in people with borderline resectable pancreatic cancer – a type where surgery might be possible but is risky. The goal is to find the best way to measure tumor response so doctors can make better treatment decisions.
Columbus, OhioAges 18 years+ - NCT07101679RecruitingPhase 2
Study of radiation, chemo, and immunotherapy for advanced pancreatic cancer
This trial tests a combination of chemotherapy (GnP), an immunotherapy drug (serplulimab), and targeted radiation (SBRT) as a first treatment for locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this triple therapy can shrink the tumor and improve outcomes.
Chengdu, SichuanAges 18–75 - NCT06984562Recruiting
Adaptive radiation therapy for advanced pancreatic cancer
This trial tests a new way of giving radiation therapy that adapts to changes in your cancer over time. It is for people with pancreatic cancer that cannot be removed by surgery but has not spread to other parts of the body.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06967662Enrolling by invitation
Plasma Adsorption to Prevent Pancreatic Cancer Spread During Surgery
This trial tests whether a special blood-filtering treatment (plasma adsorption to remove extracellular DNA) given during surgery can help prevent pancreatic cancer from spreading. It is for people with non-metastatic pancreatic cancer who are scheduled for surgery.
Moscow, Moscow OblastAges 18–75 - NCT06333314RecruitingPhase 2
Dostarlimab for advanced dMMR/MSI cancers (not colorectal or endometrial)
This trial tests a drug called dostarlimab for people with certain advanced cancers that have a specific genetic feature (dMMR/MSI-H). The goal is to see if it helps shrink or control the cancer in people who haven't had other treatments yet.
AngersAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+ - NCT05837767Recruiting
Radiation study for tumors that spread to soft tissue areas
This study looks at how a planned form of palliative radiation therapy treats certain solid cancers that have spread outside the brain to larger soft-tissue areas. It may help shrink tumors and relieve symptoms, but it also asks you to meet specific safety and treatment-timing rules.
Basking Ridge, New JerseyAges 18 years+ - NCT07823049RecruitingPhase 3
Study of XNW28012 for advanced pancreatic cancer after prior treatments
This trial tests a new drug, XNW28012, for people with advanced pancreatic cancer that has worsened after two standard chemotherapy treatments. The drug targets a protein called tissue factor on cancer cells, which might help slow or stop the cancer's growth.
Shanghai, Shanghai MunicipalityAges Any age - NCT05706129RecruitingPhase 1/Phase 2
Testing targeted imaging and therapy for advanced solid tumors
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
MelbourneAges 18 years+ - NCT06690528RecruitingPhase 2
Surgery vs. palliative care for pancreatic cancer with limited liver spread
This trial compares surgery to remove the primary tumor and up to 3 liver spots against standard palliative care for people with pancreatic cancer that has spread only to the liver (up to 3 spots). It is for those whose cancer has not grown after initial chemotherapy and who are healthy enough for surgery.
Padova, ItalyAges 18–75 - NCT06659705RecruitingPhase 2
New PET scan for early pancreatic cancer detection
This trial tests a new type of PET scan that uses a special tracer (FAPI) to get clearer images of pancreatic cancer. The goal is to find cancer earlier and better plan surgery or treatment.
Saint-CloudAges 18 years+ - NCT06562192RecruitingPhase 1
Testing a radioactive drug for advanced pancreatic, lung, breast, and colorectal cancers
This trial tests a new radioactive drug (177Lu-NNS309) for people with advanced pancreatic, lung, breast, or colorectal cancer that has not responded to prior treatments. It aims to see if the drug can target and shrink tumors.
Birmingham, AlabamaAges 18–100 - NCT04622423Recruiting
Advanced therapies for colon or pancreas liver metastases
This study tests advanced treatments for cancer that has spread to the liver, either from colon cancer or pancreatic cancer. It may help by targeting liver tumors using treatment plans and, for some participants, liver tissue samples.
Milan, MilanAges 18 years+ - NCT06453486RecruitingPhase 2
High dose radiation for pancreatic cancer after chemo
This trial tests whether giving a strong, focused dose of radiation can help people with locally advanced pancreatic cancer that has shrunk or stayed stable with first-line chemotherapy. It aims to improve outcomes for those who cannot have surgery.
Toronto, OntarioAges 18 years+ - NCT06962267RecruitingPhase 2
Study of TQB2916 with chemo for advanced pancreatic cancer
This trial tests a new drug (TQB2916) combined with standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for metastatic pancreatic cancer. It aims to see if the combination works better than chemo alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Duarte, CaliforniaAges 18 years+ - NCT04895709RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
Clovis, CaliforniaAges 18 years+ - NCT07594067RecruitingPhase 1
TCR T cells for KRAS-mutated cancers
This trial tests a new type of immune cell therapy (TCR T cells) designed to target a specific KRAS mutation (G12V) in certain advanced cancers. It may be an option for people with pancreatic, bile duct, colorectal, or lung cancer who have already tried standard treatments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06405490RecruitingPhase 2
Chemo plus immunotherapy for first-line advanced pancreatic cancer
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06572813RecruitingPhase 1/Phase 2
Combination therapy for advanced pancreatic cancer
This trial tests whether adding bortezomib and an immunotherapy drug to standard chemotherapy can help people with pancreatic cancer that has spread to other organs. It is for patients who have not had treatment or whose cancer has worsened after gemcitabine-based chemotherapy.
Hangzhou, ZhejiangAges 18–75 - NCT07306286RecruitingPhase 2
Cryoablation plus immunotherapy for advanced pancreatic cancer
This trial tests combining cryoablation (freezing tumors) with a dual-antibody drug (PD-1/CTLA-4) for people whose locally advanced pancreatic cancer has stopped responding to first-line chemotherapy (AG regimen). The goal is to see if this combination can help control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Metastatic Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic pancreatic adenocarcinoma?
- Yes. Clin2 currently lists 248 recruiting metastatic pancreatic adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic pancreatic adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic pancreatic adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.